These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15517185)

  • 1. Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers.
    Hamel ME; Sebaldt RJ; Siminoski K; Adachi JD; Papadimitropoulos E; Petrie A; Goldsmith CH
    Osteoporos Int; 2005 Feb; 16(2):208-15. PubMed ID: 15517185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
    Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures.
    Angthong C; Rodjanawijitkul S; Samart S; Angthong W
    Acta Orthop Traumatol Turc; 2013; 47(5):318-22. PubMed ID: 24164940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of osteoporosis treatment after bone mineral density testing.
    Pressman A; Forsyth B; Ettinger B; Tosteson AN
    Osteoporos Int; 2001; 12(5):337-42. PubMed ID: 11444079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec.
    Vanasse A; Dagenais P; Niyonsenga T; Grégoire JP; Courteau J; Hemiari A
    BMC Musculoskelet Disord; 2005 Jun; 6():33. PubMed ID: 15969760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for the treatment of decreased bone mineral density associated with HIV infection.
    Lin D; Rieder MJ
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005645. PubMed ID: 17443607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
    Mondy K; Powderly WG; Claxton SA; Yarasheski KH; Royal M; Stoneman JS; Hoffmann ME; Tebas P
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):426-31. PubMed ID: 15764959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
    Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
    Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study.
    Doetsch AM; Faber J; Lynnerup N; Wätjen I; Bliddal H; Danneskiold-Samsøe B
    Calcif Tissue Int; 2004 Sep; 75(3):183-8. PubMed ID: 15386160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
    Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
    Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic strategies for osteoporosis].
    Chapurlat R; Delmas PD
    Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closing the osteoporosis management gap in primary care: a secondary prevention of fracture programme.
    Brankin E; Mitchell C; Munro R;
    Curr Med Res Opin; 2005 Apr; 21(4):475-82. PubMed ID: 15899094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy's fracture clinic screening program.
    Beaton DE; Dyer S; Jiang D; Sujic R; Slater M; Sale JE; Bogoch ER;
    Osteoporos Int; 2014 Jan; 25(1):289-96. PubMed ID: 23794044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice.
    Seuffert P; Sagebien CA; McDonnell M; O'Hara DA
    Arch Osteoporos; 2016; 11():10. PubMed ID: 26847628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.